Prognostic impact of negative TTF-1 biomarker in metastatic lung adenocarcinoma treated with chemo-immunotherapy: a retrospective cohort study.

Transl Lung Cancer Res · 2025 · PMC12337030 · PMID 40799418

Europe PMC DOI

hedged sentences

0.0570

closest p · 1.1× alpha

0.1200

boldest claim

The sentences

a trend toward significanceP=0.057so close (0.05 < p ≤ 0.1)

Among patients with KRAS mutations, the G12C subtype accounted for 100% of cases in the TTF-1 − group, compared to 62.5% in the TTF-1 + group, showing a trend toward significance (P=0.057).

also in 3,729 other papers

did not reach statistical significanceP=0.11not close (p > 0.1)

PFS was also better in TTF-1 + patients, with a median of 13 months (95% CI: 8.8–17.2) compared to 10 months (95% CI: 5.1–14.9) in TTF-1 − patients, although this difference did not reach statistical significance (P=0.11) ( Figure 3 ).

also in 111,027 other papers

showed a trendP=0.12not close (p > 0.1)

In the group treated with carboplatin, the results showed a trend towards worse survival in TTF-1 − patients, with an OS of 1 month (95% CI: 0–2.3) compared to 4 months (95% CI: 0–10.4) in TTF-1 + patients (P=0.12).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.